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Patients undergoing regular hemodialysis (HD) are at an extreme risk of
acquiring bloodstream infections compared to the general population. Hepati-
tis E virus (HEV) infection is an important emerging health issue in these
patients. To date, numerous studies have investigated the seroprevalence of
HEV among HD patients across the world; however, the data are conflicting.
The present study aimed to measure the exposure rate of HD patients to HEV
infection by estimating the overall seroprevalence of HEV in this high-risk
group. A systematic literature search was carried out using five electronic data-
bases from inception to January 10, 2020, with standard keywords. Pooled sero-
prevalence estimates with 95% confidence intervals (CIs) were calculated using
a random intercept logistic regression model. The seroprevalence of HEV
increased from 6.6% between the years of 1994 and 2000 to 11.13% from 2016
to 2020. Blood transfusion was associated with a nearly 2-fold increase in the
rate of HEV seropositivity (OR = 1.99; 95% CI: 1.50-2.63, P < .0001, I2 = 6.5%).
HEV seroprevalence among patients with HD for more than 60 months was
significantly higher than those with HD for less than 60 months (27.69%, 95%
CI: 20.69%-35.99% vs 15.78%, 95%CI: 8.85%-26.57%, respectively) (P = .06). Our
results indicated increased exposure of HD patients with HEV infection over
the last decade. We concluded that blood transfusion and duration of HD are
considerable risk factors for acquiring HEV infection among HD patients.
KEYWORD S
hemodialysis, hepatitis E virus, meta-analysis, seroprevalence
1 | INTRODUCTION
Hepatitis E, which is a result of infection with the Hepati-
tis E virus (HEV), is an important public health concern
and the major etiologic agent of acute liver damage and
inflammation in humans worldwide. It has been esti-
mated that about 20 million people are infected with HEV
globally each year, leading to 3.3 million symptomatic
cases and around 44 000 deaths.1 In developing countries,
HEV is mainly transmitted through the consumption of
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contaminated water and food due to poor hygiene condi-
tions that result in large-scale outbreaks.2,3 In industrial-
ized countries, transmission usually occurs via alternative
routes, such as the consumption of undercooked pork as a
foodborne zoonosis, which likely contributes to the spo-
radic cases of acute hepatitis and fulminant hepatic fail-
ure, particularly among immunosuppressed individuals.4
Transmission via blood transfusion and blood products,
such as packed red blood cells and platelets, has also been
demonstrated, especially in developed countries.2,5
Chronic kidney disease and resulting end-stage renal
disease (ESRD) have been recognized as serious chal-
lenges in global public health, and hemodialysis (HD)
continues to be the predominant therapeutic approach for
the treatment of ESRD patients in most countries. Perito-
neal dialysis and renal transplantation are two other
major types of renal replacement therapies for ESRD
patients and constitute 20% of overall dialysis treatment.6,7
It is well known that patients on HD are at increased risk
for acquiring viral infections, and sharing dialysis
machines, frequent blood transfusions, repeated hospitali-
zations, and impaired cellular immunity make them par-
ticularly prone to bloodborne viruses.8 Previous studies
have documented that chronic liver diseases caused by
the hepatitis C (HCV) and hepatitis B (HBV) viruses are
more prevalent in HD and thalassemia major patients
than the general population.8–11
HEV infection is another emerging health issue in
HD patients, which can deteriorate patients’ conditions.
To date, there are some varying reports of the seropreva-
lence of HEV in HD patients from different countries
worldwide. However, there is a need for an updated study
reporting the pooled seroprevalence of HEV in this high-
risk group. Hence, this systematic review and meta-anal-
ysis aimed at estimating the seroprevalence of HEV
among HD patients throughout the world.
2 | MATERIALS AND METHODS
2.1 | Search strategy
We performed a systematic review and meta-analysis of
the literature according to the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guideline.12 The searches were limited to English-lan-
guage studies reporting the seroprevalence of HEV
among HD patients around the world. PubMed, Web of
Science, Scopus, Embase, and Google Scholar were
searched from inception until January 10, 2020. The full
FIGURE 1 Flowchart presenting
the steps of literature search and
selection [Color figure can be viewed at
wileyonlinelibrary.com]
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TABLE 1 Characteristics of studies included in the systematic review and meta-analysis





Halfon (21) 1994 France 147 62.3 ELISA/Western blot 16 —
Knödler (22) 1994 Germany 150 — ELISA/Western blot 5 —
Buti (23) 1995 Spain 50 — ELISA/Western blot 3 —
Cengiz (24) 1996 Turkey 72 45.5 ELISA 10 56.4
Fabrizi (25) 1996 Italy 204 — ELISA 6 —
Gessoni (26) 1996 Italy 193 59.5 ELISA 18 —
Guiserix (27) 1996 France 62 — ELISA 2 —
Psichogiou (19) 1996 Greece 420 57.3 ELISA 27 61.4
Fabrizi (28) 1997 Italy 204 61.1 ELISA 6 39
Parana (29) 1997 Brazil 392 — ELISA 0 —
Abdel Hady (30) 1998 Egypt 96 — ELISA 38 —
Arinsoy (31) 1998 Turkey 52 — ELISA 9 —
Gessoni (32) 1998 Italy 247 — ELISA 23 —
Dalekos (33) 1998 Greece 211 — ELISA/Western blot 7 —
Sylvan (34) 1998 Sweden 182 — ELISA 11 —
Agarwal (35) 1999 India 64 38 ELISA 26 —
Kilic (36) 1999 Turkey 70 — ELISA 4 —
Mateos (37) 1999 Spain 63 — ELISA/Western blot 4 62
Trinta (38) 2001 Brazil 65 65.1 ELISA 4 —
Irshad (39) 2002 India 58 — ELISA 21 —
Ayoola (40) 2002 Saudi Arabia 83 39 ELISA 6 —
Kiesslich (41) 2002 Brazil 192 — ELISA 1 —
Ding (42) 2003 Japan 60 46.2 ELISA 18 —
Mitsui (43) 2004 Japan 416 60.1 ELISA 39 91.2
Stefanidis (44) 2004 Greece 351 60 ELISA 17 49
Lee (45) 2005 Taiwan 400 57 ELISA 124 32
Taremi (46) 2005 Iran 324 53.5 ELISA 24 53.45
Kikuchi (47) 2006 Japan 300 60.1 ELISA 57 116.4
Pourahmad (48) 2009 Iran 43 59.3 ELISA 3 108
Uçar (49) 2009 Turkey 92 55 ELISA 19 66
Mina (50) 2010 Greece 366 60.5 ELISA 15 49.2
Khameneh (51) 2011 Iran 65 — ELISA 22 —
El Sayed Zaki (20) 2013 Egypt 30 — ELISA 0 —
Harrison (52) 2013 United Kingdom 76 — ELISA 28 —
Mobaien (53) 2013 Iran 93 57 ELISA 25 —
Scotto (54) 2013 Italy 104 65.1 ELISA/Western blot 10 —
Zekavat (55) 2013 Iran 80 55.69 ELISA 5 15.6
Ben-Ayed (56) 2014 Tunisia 286 54.86 ELISA 29 —
Kelishadi (57) 2014 Iran 149 56 ELISA 0 —
Mousavi (58) 2014 Iran 47 55.27 ELISA 5 —
Alavian (59) 2015 Iran 274 59.9 ELISA 78 34.6
El Sayed Zaki (60) 2015 Egypt 96 46.6 ELISA 22 —
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details of the search strategy for each database are given
in the Appendix. The bibliographies of retrieved articles
were also reviewed for additional relevant studies that
were likely missed in the primary search. All identified
articles were imported to the EndNote software version
X8 (Thomson Reuters, California) for further evaluation.
2.2 | Selection criteria
The inclusion criteria were as follows: (a) studies reporting
the seroprevalence rate of anti-HEV IgG among HD
patients across the world; (b) conference abstracts, letters
to the editor, short communications, and English abstracts
with sufficient data; and (c) studies performed by enzyme-
linked immunosorbent assay (ELISA) and Western blot.
Studies meeting one of the following criteria were
excluded: (a) reviews and case reports; (b) studies investi-
gating the seroprevalence rate of anti-HEV IgM among
HD patients; (c) studies investigating the molecular preva-
lence of HEV in HD patients; (d) studies on patients under
other types of dialysis such as peritoneal dialysis; and (e)
studies assessing the incidence of HEV among patients
undergoing HD, such as prospective studies.
2.3 | Data extraction and quality
assessment
Titles and abstracts were screened independently by two
reviewers, and studies that were not relevant to the study
were excluded. Then, the full texts of all potentially eligi-
ble studies were obtained and further evaluated, and any
disagreements were resolved by consultation with a third
reviewer. A checklist based on the guidelines of Strength-
ening the Reporting of Observational Studies in Epidemi-
ology (STROBE) was used for quality assessment of the
retrieved studies.13 The checklist contains 12 questions
that cover different methodological aspects. According to
the checklist, the highest score was 12, representing the
highest quality, and the minimum acceptable score was
8. Finally, studies obtaining the minimum score and over
were considered eligible for the main meta-analysis. For
each eligible study, we extracted data on the following
variables: author name, publication year, study location,
total sample size, gender and age of patients, duration of
HD, detection method, number of HEV-positive cases,
and a history of blood transfusion. The extracted data
were imported into a predesigned Excel spreadsheet
(Microsoft Corporation, Redmond, Washington).
2.4 | Statistical methods
To estimate the pooled HEV seroprevalence among HD
patients, a random intercept logistic regression model
was implemented.14 The logit transformation was used to
stabilize the variance and normalize their distribution,
and the Clopper-Pearson method was applied to estimate
the 95% exact confidence intervals (CIs) for proportions.15
A standard continuity correction of 0.5 was added to the
studies with a prevalence of zero.16 To explore the
TABLE 1 (Continued)





Eini (61) 2015 Iran 153 — ELISA 30 33
Scotto (62) 2015 Italy 231 — ELISA/Western blot 14 —
Debes (63) 2016 Argentina 81 — ELISA 8 —
Hajiahmadi (64) 2016 Iran 149 55.09 ELISA 6 —
Pisano (65) 2016 Argentina 82 60 ELISA 8 —
Naziri (66) 2016 Iran 300 54 ELISA 12 —
Ricco (67) 2016 Italy 88 74.3 ELISA 22 —
Yılmaz (68) 2017 Turkey 66 — ELISA 28 —
Sheng (69) 2017 China 170 — ELISA 82 —
Altuglu (70) 2018 Turkey 68 49.2 ELISA 1 37.9
de Oliveira (71) 2018 Brazil 310 — ELISA/Western blot 8 —
Kuznetsova (72) 2018 Estonia 176 50.9 ELISA/Western blot 7 —
Lemos (73) 2019 Brazil 286 — ELISA 70 —
Mrzljak (74) 2020 Croatia 394 70.5 ELISA 110 —
Abbreviations: HEV, hepatitis E virus.
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possible sources of heterogeneity, subgroup analyses were
performed based on the publication year, gender, age,
detection method, study location, history of blood trans-
fusion, and duration of HD. To measure the heterogene-
ity among the included publications, I-square statistics
(I2) was performed, in which the result is presented as a
percentage. I2 values of 25%, 50%, and 75% are indicative
of low, moderate, and high levels of heterogeneity,
respectively.17 All statistical tests and time-trend graph
productions were performed using R package Meta18
(version 4.9.9, R Foundation for Statistical Computing,
Vienna, Austria), and P values of less than 0.05 were con-
sidered statistically significant.
3 | RESULTS
3.1 | Literature search
In the initial search, 615 articles were identified from five
international electronic databases. A total of 277 dupli-
cates was excluded, and then, 338 articles were screened
by title and abstract, which led to the elimination of 260
articles. The remaining 78 articles were checked for agree-
ment with the inclusion and exclusion criteria through
the full-text review. After full-text screening, 28 articles
were excluded because: 12 articles were not relevant to
the subject, 10 articles included duplicated data, 4 articles
had no full-text available, 1 article determined the inci-
dence of HEV among HD patients, and one article did not
present sufficient data. In addition, six relevant articles
were found and included by a manual search of the refer-
ence lists of the identified articles. Finally, 56 articles were
included in this systematic review and meta-analysis. Fig-
ure 1 represents the process of literature retrieval and
screening using a flow chart.
3.2 | Study characteristics
In this meta-analysis, a total of 56 studies, with a total of
9483 patients from 20 countries, were included. The publica-
tion date of articles ranged from 1994 to 2020. The character-
istics of eligible studies in this systematic review and meta-
analysis are summarized in Table 1. The largest study19
included 420 patients, and the smallest20 included 30 HD
patients. Most studies investigating the seroprevalence of
HEV among patients undergoing HD were from Iran
(n = 11), Italy (n = 7), and Turkey (n = 6). Of the 56 studies
included, 17 provided information on patients’ gender, 7
studies provided data on patients’ age, 4 had information on
the duration of HD, and 6 studies presented data on the his-
tory of blood transfusion. Overall, 53.5% of the studies
(n = 30) were performed before 2010, and 46.5% of the stud-
ies (n = 26) were performed after 2010.
3.3 | Seroprevalence of HEV infection
among HD patients
The pooled estimated seroprevalence of HEV infection in
HD patients around the world was 9.31% (95% CI: 6.83%-
12.57%), and the range was from 48.24%20 to 0%19,21,22in
FIGURE 2 Forest plot of the seroprevalence of hepatitis E
virus (HEV) infection among HD patients, according to the
random-effect model, stratified by study year (before and after
2010) [Color figure can be viewed at wileyonlinelibrary.com]
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the selected individual studies. The results of the het-
erogeneity test indicated a significant heterogeneity
among all studies that were analyzed in this meta-anal-
ysis, so the random-effects model was used to pool the
data. The highest and lowest seroprevalence rates of
HEV were found in HD patients from China and Brazil,
respectively (48.24%, 95% CI: 40.82%-55.73% vs 1.77%,
95% CI: 0.23%-12.31%). To explore responsible factors
for heterogeneity, a subgroup analysis was conducted.
This analysis showed that the diagnostic method, dura-
tion of HD, age, study year, and study location are
responsible for heterogeneity.









subgroups; χ2 test (P-value)
Overall 56 9.31 (6.83-12.57) 95.9%, P < .01
Diagnostic method ELISA 47 10.37 (7.30-14.54) 96.6%, P < .01 P = .005†
ELISA/Western blot 9 5.14 (3.62-7.25) 55.4%, P = .01
Duration of HD (mo) <60 4 15.78 (8.85-26.57) 87.8%, P < .01 P = .06
>60 2 27.69 (20.69-35.99) 0%, P = .1
Age (y) <40 6 4.91 (1.76-12.97) 52.9%, P = .09 P = .1
>40 7 12.19 (6.42-21.93) 94.9%, P < .01
Gender Male 17 10.86 (6.66-17.20) 94.0%, P = .01 P = .7
Female 17 9.54 (5.62-15.74) 91.5%, P = .01
Study year 1994-2000 18 6.60 (3.82-11.16) 92.9%, P < .01 P = .6
2001-2005 9 9.81 (4.54-19.93) 96.4%, P < .01
2006-2010 4 10.77 (5.16-21.12) 89.4%, P < .01
2011-2015 13 11.70 (6.15-21.15) 95.5%, P < .01
2016-2020 12 11.13 (5.59-20.94) 96.8%, P < .01
Study location Argentina 2 9.82 (6.10-15.42) 0%, P = .98 P < .0001†
Brazil 5 1.77 (0.23-12.31) 96.2%, P < .01
China 1 48.24 (40.82-55.73) NA, NA
Croatia 1 27.92 (23.71-32.55) NA, NA
Egypt 3 12.78 (1.54-57.82) 96.6%, P = .05
Estonia 1 3.98 (1.91-8.11) NA, NA
France 2 7.63 (3.29-16.72) 28.2%, P = .09
Germany 1 3.33 (1.39-7.76) NA, NA
Greece 4 4.90 (3.86-6.19) 0%, P = .30
India 2 38.52 (30.32-47.43) 0%, P = .62
Iran 11 9.11 (4.53-17.49) 95.0%, P < .01
Italy 7 7.52 (4.39-12.58) 85.8%, P < .01
Japan 3 17.26 (9.87-28.44) 88.7%, P < .01
Saudi Arabia 1 7.23 (3.28-15.17) NA, NA
Spain 2 6.19 (2.98-12.43) 0%, P = .94
Sweden 1 6.04 (3.38-10.58) NA, NA
Taiwan 1 31.00 (26.66-35.70) NA, NA
Tunisia 1 10.14 (7.14-14.21) NA, NA
Turkey 6 12.92 (5.65-26.87) 89.6%, P < .01
United Kingdom 1 36.84 (26.79-48.18) NA, NA
Abbreviations: ELISA, enzyme-linked immunosorbent assay; HEV, hepatitis E virus; NA, Not applicable.
†Statistically significant (indicated as bold values) .
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We divided the individual studies into two time
periods of publication, before and after 2010. The polled
estimated seroprevalence rates of HEV infection before
and after 2010 were different, 8.1% (95% CI: 5.36%-
12.05%) and 10.94% (95% CI: 6.91%-16.89%), respectively
(Figure 2). However, the difference was not statistically
significant (P = .3). Among studies performed after 2010,
the maximum and minimum seroprevalence of HEV
among HD patients were found in China and Estonia,
respectively (48.24%, 95%CI: 40.82%-55.73% vs 3.98%, 95%
CI: 1.91%-8.11%).
The seroprevalence of HEV among patients with HD
for more than 60 months was significantly higher than
those with HD for less than 60 months (27.69%, 95%CI:
20.69%-35.99% vs 15.78%, 95%CI: 8.85%-26.57%, respec-
tively) (P = .06). Furthermore, the proportion of HEV
seropositivity among male cases undergoing HD was
slightly higher than female cases (10.86%, 95%CI: 6.66%-
17.20% vs 9.54%, 95%CI: 5.62%-15.74%, respectively)
(P = .7). With respect to HEV serodetection techniques in
blood samples of HD patients, ELISA with or without
Western blot assay as a confirmatory test was used. HEV
seroprevalence rates were 10.37% (95%CI: 7.30%-14.54%)
and 5.14% (95%CI: 3.62%-7.25%) when ELISA and
ELISA/Western blot assays were used, respectively, and
the difference was statistically significant (P = .005).
Table 2 indicates more detailed information on the sero-
prevalence of HEV infection among HD patients for sub-
groups. In addition, our results showed that blood
transfusion is associated with a nearly 2-fold increase in
the rate of HEV seropositivity (OR = 1.99; 95%CI: 1.50-
2.63, P < .0001, I2 = 6.5%) (Figure 3).
3.4 | Time trend analysis
Time trend analysis was performed to investigate changes
in the seroprevalence of HEV infection over time in the
world (Figure 4). According to this analysis, the seroprev-
alence of HEV was the lowest (6.6%; 95% CI: 3.82%-
11.16%) between 1994 and 2000. From 2001 until 2020,
the number of HEV-seropositive cases among HD
patients dramatically increased, and the seroprevalence
was 11.13% (95% CI: 5.59%-20.94%) between 2016 and
2020 (Table 2).
4 | DISCUSSION
The present study, for the first time, estimated the sero-
prevalence of HEV in HD patients in a systematic review
and meta-analysis setting. Patients undergoing HD are
characterized by abnormalities in both the adaptive and
innate immune systems, making them susceptible to
infections.75 After cardiovascular complications, infec-
tions are the second major leading cause of death in HD
patients.76 Among the different bloodborne viral infec-
tions, hepatitis and human immunodeficiency viruses are
the most common problems in HD units, as well as the
general population.77 Hepatitis E is generally considered
an acute self-limited liver disease with no progression to
chronic stages. However, recent studies have shown that
chronic HEV infection and cirrhosis may occur,
FIGURE 3 Forest plot of the association between blood
transfusion and hepatitis E virus (HEV) seropositivity according to
the random-effect model [Color figure can be viewed at
wileyonlinelibrary.com]
FIGURE 4 Time trend in the
seroprevalence of hepatitis E virus (HEV)
among HD patients [Color figure can be
viewed at wileyonlinelibrary.com]
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especially in immunocompromised individuals such as
HD patients.78 A meta-analysis conducted by Haffar et al
showed a positive relationship between HD and HEV
seroprevalence.79 According to their findings, the sero-
prevalence of HEV was more prevalent in HD patients
compared with the non-HD control (OR 2.47, 95% CI:
1.79-3.40, I2 = 75.2%, P < .01). In another review study
by Hosseini-Moghaddam et al, several risk factors have
been identified for HEV infection in HD patients, includ-
ing older age, living in rural vs urban areas, low educa-
tion, and duration of HD.80
One of the most important findings of our study is
that the overall seroprevalence of HEV infection in
patients on HD has been increasing over the last few
years around the world, which should be considered an
emerging public health threat. According to our findings,
the pooled seroprevalence of HEV among HD patients
was 9.31%, and the highest rate of seroprevalence was
seen among Chinese patients, followed by Indian, British,
and Taiwanese patients. Interestingly, some European
countries, such as the United Kingdom and Croatia,
show a high seroprevalence of HEV among their HD
patients. This can be explained by the fact that, over the
past decade, the incidence and prevalence of HEV infec-
tion, particularly with genotype 3 (G3) HEV, has been
steadily growing in many developed countries, including
countries of the European Union.81 It should be noted
that HEV G3 is associated more with the establishment
of persistent infection in immunocompromised patients,
leading to the development of chronic hepatitis and seri-
ous liver complications.82
Our analysis suggested that the seroprevalence of
HEV in HD units varies throughout the world. In the
past, HEV infection was thought to be limited to develop-
ing countries with poor hygiene and sanitary conditions.
Nowadays, this assumption has been challenged because
most developed countries are also experiencing a high
prevalence rate of HEV. As an explanation, differences in
culinary culture in different regional areas can result in a
wide variety of HEV prevalence rates. In developed coun-
tries, the transmission of HEV to humans occurs mainly
via the consumption of raw pork products, particularly
pork liver.83 Zoonotic HEV G3 strains were documented
to mostly circulate between humans, swine, and wild
boar in Europe.84
Generally, immunization is an effective and safe mea-
sure in controlling infectious diseases, and HEV infection
is not spared. There is no FDA-approved vaccine cur-
rently available against HEV, and most HEV vaccine can-
didates are based on recombinant expressed HEV-capsid
proteins. HEV 239 is the only recombinant HEV vaccine
approved in China since 2011, which exhibited high
effectiveness in preventing HEV infection in the general
population in China.85 Therefore, vaccination schedules
in HD patients can play an effective role in reducing
HEV prevalence. Another suggestion for preventing hep-
atitis E transmission is taking preventive measures at the
level of the community (eg, water decontamination,
improved hygiene and sanitation) and the personal level
(eg, avoid eating raw or undercooked meat).
HEV is recognized as a serious public health concern
in HD patients both in developed and developing coun-
tries. Generally, global immunization in humans and ani-
mals, especially in pigs; improvements in sanitation
conditions in HEV-endemic areas; and avoiding the con-
sumption of suspicious HEV-infested drinking water and
undercooked shellfish, meat, vegetables, and fruits can be
considered the best strategies for decreasing the preva-
lence rate. On the other hand, it should be noted that our
estimation can be affected by some limitations, such as a
small number and low geographical coverage of the stud-
ies. Until now, there are no published data on the sero-
prevalence of HEV in this high-risk population in a large
number of countries, and performing updated investiga-
tions in these areas is highly suggested.
5 | CONCLUSIONS
In conclusion, the overall seroprevalence of HEV in
patients undergoing HD is increasing over the past years
in the world, which should be considered an emerging
public health issue. We also demonstrated that blood
transfusion is significantly associated with an increased
rate of HEV seropositivity. There are no data regarding
the seroprevalence of HEV in HD patients in some coun-
tries. Therefore, performing screening tests for HEV in
HD patients in other regions of the world is highly rec-
ommended to obtain more reliable estimates of the over-
all seroprevalence of HEV.
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APPENDIX A.: THE DETAILS OF SEARCH
TERMS FOR EACH DATABASE
Databases Search criteria
PubMed (“renal dialysis”[mesh terms] OR dialyses, renal
OR renal dialyses OR dialysis, renal OR
hemodialysis OR Hemodialyses OR dialysis,
extracorporeal OR dialyses, extracorporeal OR
extracorporeal dialyses OR extracorporeal
dialysis) AND (“hepatitis E"[mesh terms] OR
“hepatitis E virus”[mesh terms] OR hepatitis,
water-borne OR Hepatitides, water-borne OR
hepatitis, water borne OR water-borne
Hepatitides OR water-borne hepatitis OR ET-
NANBH OR hepatitis, viral, non-A, non-B,
Enterically-transmitted OR Enterically-
transmitted non-A, non-B hepatitis OR
Enterically transmitted non A, non B hepatitis
OR epidemic non-A, non-B hepatitis OR
epidemic non A, non B hepatitis OR HEV)
Embase (“hepatitis e”/exp OR “enterically transmitted
non a non b hepatitis” OR “epidemic non a
non b hepatitis” OR ‘hepatitis e’ OR “hepatitis
e virus”/exp OR “hev [hepatitis]” OR ‘hepatitis
e virus’ OR “hepatitis virus e”) AND
(“hemodialysis”/exp OR “blood dialysis” OR
“chronic haemodialysis” OR “chronic
hemodialysis” OR “chronic intermittent
haemodialysis” OR “chronic intermittent
hemodialysis” OR “dialysis center” OR
“dialysis, blood” OR “extracorporeal blood
cleansing” OR “extracorporeal dialysis” OR
‘haemodialysis' OR “haemodialysis center” OR
“haemodialysis Centre” OR “haemodialysis
department” OR “haemodialysis unit” OR
“haemodialysis units, hospital” OR
“hemodialyse” OR ‘hemodialysis’ OR
“hemodialysis center” OR “hemodialysis
department” OR “hemodialysis unit” OR
“hemodialysis units, hospital” OR
“hemorenodialysis” OR “hemotrialysate” OR
“intermittent chronic haemodialysis” OR
“intermittent chronic hemodialysis” OR
‘intermittent haemodialysis' OR ‘intermittent
hemodialysis’ OR “renal dialysis”)
Scopus TITLE-ABS-KEY ((“hepatitis e" OR “enterically
transmitted non a non b hepatitis” OR
(Continues)
Databases Search criteria
“epidemic non a non b hepatitis” OR “hepatitis
e" OR “hepatitis e virus” OR “hev [hepatitis]”
OR “hepatitis e virus” OR “hepatitis virus e")
AND (“hemodialysis” OR “blood dialysis” OR
“chronic haemodialysis” OR “chronic
hemodialysis” OR “chronic intermittent
haemodialysis” OR “chronic intermittent
hemodialysis” OR “dialysis center” OR
“dialysis, blood” OR “extracorporeal blood
cleansing” OR “extracorporeal dialysis” OR
“haemodialysis” OR “haemodialysis center”
OR “haemodialysis Centre" OR “haemodialysis
department” OR “haemodialysis unit” OR
“haemodialysis units, hospital” OR
“hemodialyse” OR “hemodialysis” OR
“hemodialysis center” OR “hemodialysis
department” OR “hemodialysis unit” OR
“hemodialysis units, hospital” OR
“hemorenodialysis” OR “hemotrialysate” OR
“intermittent chronic haemodialysis” OR
“intermittent chronic hemodialysis” OR
“intermittent haemodialysis” OR “intermittent
hemodialysis” OR “renal dialysis”))
Web of
science
TS = ((“hepatitis e" OR “enterically transmitted
non a non b hepatitis” OR “epidemic non a
non b hepatitis” OR “hepatitis e" OR “hepatitis
e virus” OR “hev [hepatitis]” OR “hepatitis e
virus” OR “hepatitis virus e") AND
(“hemodialysis” OR “blood dialysis” OR
“chronic haemodialysis” OR “chronic
hemodialysis” OR “chronic intermittent
haemodialysis” OR “chronic intermittent
hemodialysis” OR “dialysis center” OR
“dialysis, blood” OR “extracorporeal blood
cleansing” OR “extracorporeal dialysis” OR
“haemodialysis” OR “haemodialysis center”
OR “haemodialysis Centre" OR “haemodialysis
department” OR “haemodialysis unit” OR
“haemodialysis units, hospital” OR
“hemodialyse” OR “hemodialysis” OR
“hemodialysis center” OR “hemodialysis
department” OR “hemodialysis unit” OR
“hemodialysis units, hospital” OR
“hemorenodialysis” OR “hemotrialysate” OR
“intermittent chronic haemodialysis” OR
“intermittent chronic hemodialysis” OR
“intermittent haemodialysis” OR “intermittent
hemodialysis” OR “renal dialysis”))
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